×
CLOSE
Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Neurology
Oncology
ActivMAb
®
Antigen Virus
In Vivo Discovery
In Vitro Discovery
Protein Optimization
Antigen Discovery
ActivMAb
®
Contact
News & Publications
News
Publications
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Events
Presentations
Careers
Contact Us
Science in the service of medicine
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab Neurology
Pepinemab Immuno-Oncology
Research & Development Programs
Clinical Trials
Neurology
Oncology
ActivMAb
®
ActivMAb
®
Antigen Virus
In Vivo Discovery
In Vitro Discovery
Protein Optimization
Antigen Discovery
Contact Us
News & Publications
News
Publications
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Events
Presentations
Careers
Contact Us
ActivMab
®
Protein Optimization
Directed Evolution of Membrane Proteins using Vaccinia Virus Libraries
Many multi-pass membrane proteins are difficult to over-express for research needs including Antibody Discovery and Structural Studies.
Vaccinex can improve expression of these difficult targets by combining
mutagenesis
with our
viral library technology.
ActivMAb
®
in Action:
“A Vaccinia-based system for directed evolution of GPCRs in mammalian cells”
Read our 2023 paper in Nature Communications
Contact us for a quote or to learn more about ActivMab
®
Discovery Services
You can now easily find, order, and purchase Vaccinex’s catalog and custom services on
Science Exchange
If you are interested in learning more about ActivMab®, please email us at
activmab@vaccinex.com
.
Learn more about ActivMab
®
Technology
Antigen Virus
In Vivo Discovery
In Vitro Discovery
Protein Optimization